Cargando…

Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation

We present the case of a 45-year-old man with atrial fibrillation and morbid obesity (weight 128 kg, height 168 cm, BMI 45.4) who was switched from Warfarin 5 mg once daily to Apixaban 5 mg twice daily because he did not achieve at least 60% of the time in therapeutic range. We performed serial dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Vincenzo, Paccone, Andrea, Rago, Anna, Maddaloni, Valeria, Iafusco, Dario, Proietti, Riccardo, Atripaldi, Umberto, D’Onofrio, Antonio, Golino, Paolo, Nigro, Gerardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061727/ https://www.ncbi.nlm.nih.gov/pubmed/32184692 http://dx.doi.org/10.2147/JBM.S229526

Ejemplares similares

Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
por: Russo, Vincenzo, et al.
Publicado: (2019)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
por: Rago, Anna, et al.
Publicado: (2023)

The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator
por: Russo, Vincenzo, et al.
Publicado: (2020)

Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Case report: Lamin A/C gene mutation in patient with drug-induced type 1 Brugada syndrome at high arrhythmic risk
por: Russo, Vincenzo, et al.
Publicado: (2023)

Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry
por: Russo, Vincenzo, et al.
Publicado: (2022)

Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score–Matched Study
por: Rago, Anna, et al.
Publicado: (2020)

Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study
por: Rago, Anna, et al.
Publicado: (2021)

Inappropriate shocks due to air entrapment in patients with subcutaneous implantable cardioverter‐defibrillator: A meta‐summary of case reports
por: Iavarone, Michele, et al.
Publicado: (2022)

Atrial fibrillation burden in Myotonic Dystrophy type 1 patients implanted with dual chamber pacemaker: the efficacy of the overdrive atrial algorithm at 2 year follow-up
por: RUSSO, VINCENZO, et al.
Publicado: (2013)

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

The effect of atrial preference pacing on atrial fibrillation electrophysiological substrate in Myotonic Dystrophy type 1 population
por: RUSSO, VINCENZO, et al.
Publicado: (2014)

Device-Related Complications and Inappropriate Therapies Among Subcutaneous vs. Transvenous Implantable Defibrillator Recipients: Insight Monaldi Rhythm Registry
por: Russo, Vincenzo, et al.
Publicado: (2022)

Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study
por: D’Onofrio, Antonio, et al.
Publicado: (2018)

Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study
por: NIGRO, GERARDO, et al.
Publicado: (2012)

COVID-19 and Heart: From Clinical Features to Pharmacological Implications
por: Russo, Vincenzo, et al.
Publicado: (2020)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram Analysis
por: Russo, Vincenzo, et al.
Publicado: (2014)

Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation
por: Carbone, Andreina, et al.
Publicado: (2022)

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
por: Ioannou, Adam, et al.
Publicado: (2017)

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
por: Kirchhof, Paulus, et al.
Publicado: (2018)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

Stroke, Dementia, and Atrial Fibrillation: From Pathophysiologic Association to Pharmacological Implications
por: Russo, Vincenzo, et al.
Publicado: (2020)

Lupus Antibody Mimicking Reduced Plasmatic Coagulation in a Patient With Atrial Fibrillation and Ischemic Stroke
por: Huseynov, Aydin, et al.
Publicado: (2020)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation
por: Kyriakou, Elias, et al.
Publicado: (2018)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Cost-effectiveness of Apixaban for Stroke Prevention in Patients with Atrial Fibrillation in Algeria
por: Aoudia, Yazid, et al.
Publicado: (2017)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Increased dispersion of ventricular repolarization in emery dreifuss muscular dystrophy patients
por: Russo, Vincenzo, et al.
Publicado: (2012)

Early evaluation of atrial high rate episodes using remote monitoring in pacemaker patients: Results from the RAPID study
por: Russo, Vincenzo, et al.
Publicado: (2022)

Ventricular fibrillation induced by coagulating mode bipolar electrocautery during pacemaker implantation in Myotonic Dystrophy type 1 patient
por: RUSSO, VINCENZO, et al.
Publicado: (2014)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hfmcc2kvhns7dm4komb73e72fj